3 October 2019 - Japan’s “overly restrictive” drug pricing policies risk diverting foreign direct investment to China and other markets, the chief executive of Bristol-Myers Squibb said on Thursday.

The Japanese government made reforms in 2018 that change how its national health system pays for new and innovative drugs.

But those changes are not science-based and favour large domestic drugmakers over foreign and smaller players, Giovanni Caforio told a news conference in Tokyo.

Read Reuters article